Role of natural antibodies in immune homeostasis: IVIg perspective

Autoimmunity Reviews

Volumn 7, Issue 6, 2008, Pages 440-444

  Vani, Janakiraman ^a,b,c   Elluru, Sriramulu ^a,b,c,d   Negi, Vir Singh ^e   Lacroix Desmazes, Sébastien ^a,b,c   Kazatchkine, Michel D ^a,b,c   Bayary, Jagadeesh ^a,b,c   Kaveri, Srini V ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^e JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Autoimmune diseases; B cells; Dendritic cells; Intravenous immunoglobulin; Natural antibodies; T cells

Indexed keywords

ANTIBODY; CD4 ANTIGEN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5B; COMPLEMENT COMPONENT C9; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; CYTOKINE; FC RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN IDIOTYPE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 22; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CHURG STRAUSS SYNDROME; COMPLEMENT ACTIVATION; DENDRITIC CELL; DRUG MECHANISM; EFFECTOR CELL; GENE EXPRESSION; HOMEOSTASIS; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATORY DISEASE; LYMPHOCYTE DIFFERENTIATION; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

AUTOANTIBODIES; B-LYMPHOCYTES; COMPLEMENT INACTIVATOR PROTEINS; CYTOKINES; DENDRITIC CELLS; HOMEOSTASIS; HUMANS; IMMUNOGLOBULIN IDIOTYPES; IMMUNOGLOBULINS, INTRAVENOUS; RECEPTORS, CELL SURFACE; RECEPTORS, FC; T-LYMPHOCYTES;

EID: 51749109351     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2008.04.011     Document Type: Review

References (40)

1. Bayry J., Lacroix-Desmazes S., Kazatchkine M.D., and Kaveri S.V. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nat Clin Pract Rheumatol 3 (2007) 262-272
2. Gold R., Stangel M., and Dalakas M.C. Drug insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat Clin Pract Neurol 3 (2007) 36-44
3. Kazatchkine M.D., and Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345 (2001) 747-755
4. Bayry J., Lacroix-Desmazes S., Kazatchkine M.D., and Kaveri S.V. Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era?. Trends Pharmacol Sci 25 (2004) 306-310
5. Samuelsson A., Towers T.L., and Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291 (2001) 484-486
6. Kaneko Y., Nimmerjahn F., and Ravetch J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313 (2006) 670-673
7. von Gunten S., Schaub A., Vogel M., Stadler B.M., Miescher S., and Simon H.U. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood 108 (2006) 4255-4259
8. von Gunten S., Vogel M., Schaub A., et al. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. J Allergy Clin Immunol 119 (2007) 1005-1011
9. Fuchs S., Feferman T., Meidler R., et al. A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis. J Neuroimmunol 194 (2008) 89-96
10. Shoenfeld Y., Rauova L., Gilburd B., et al. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol 14 (2002) 1303-1311
11. Blank M., Anafi L., Zandman-Goddard G., et al. The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int Immunol 19 (2007) 857-865
12. Sherer Y., and Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2 (2006) 99-106
13. Crow A.R., Song S., Semple J.W., Freedman J., and Lazarus A.H. A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg?. Blood 109 (2007) 155-158
14. Raju R., and Dalakas M.C. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 128 (2005) 1887-1896
15. Ghielmetti M., Bellis M., Spycher M.O., Miescher S., and Vergeres G. Gene expression profiling of the effects of intravenous immunoglobulin in human whole blood. Mol Immunol 43 (2006) 939-949
16. Arumugam T.V., Tang S.C., Lathia J.D., et al. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc Natl Acad Sci U S A 104 (2007) 14104-14109
17. de Grandmont M.J., Racine C., Roy A., Lemieux R., and Neron S. Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgG. Blood 101 (2003) 3065-3073
18. Crow A.R., Song S., Freedman J., et al. IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity. Blood 102 (2003) 558-560
19. Le Pottier L., Bendaoud B., Dueymes M., et al. BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer. J Clin Immunol 27 (2007) 257-265
20. Prasad N.K., Papoff G., Zeuner A., et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 161 (1998) 3781-3790
21. Miyara M., and Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 13 (2007) 108-116
22. Roncarolo M.G., and Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 7 (2007) 585-598
23. Misra N., Bayry J., Lacroix-Desmazes S., Kazatchkine M.D., and Kaveri S.V. Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 172 (2004) 4676-4680
24. Bayry J., Triebel F., Kaveri S.V., and Tough D.F. Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells. J Immunol 178 (2007) 4184-4193
25. Bayry J., Kaveri S.V., and Tough D.F. Do activated human dendritic cells diminish the suppressive functions of CD4+,CD25+ regulatory T cells? Comment on the article by van Amelsfort et al. Arthritis Rheum 56 (2007) 3874-3876
26. Ephrem A., Chamat S., Miquel C., et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111 (2008) 715-722
27. Kessel A., Ammuri H., Peri R., et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 179 (2007) 5571-5575
28. Bayry J., Siberil S., Triebel F., Tough D.F., and Kaveri S.V. Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy. Drug Discov Today 12 (2007) 548-552
29. Bayry J., Lacroix-Desmazes S., Dasgupta S., Kazatchkine M.D., and Kaveri S.V. Efficacy of regulatory T-cell immunotherapy: are inflammatory cytokines key determinants?. Nat Rev Immunol 8 (2008) 1p following 86
30. Steinman R.M., and Banchereau J. Taking dendritic cells into medicine. Nature 449 (2007) 419-426
31. Bayry J., Lacroix-Desmazes S., Carbonneil C., et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101 (2003) 758-765
32. Bayry J., Lacroix-Desmazes S., Delignat S., et al. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. Arthritis Rheum 48 (2003) 3497-3502
33. Bayry J., Lacroix-Desmazes S., Kazatchkine M.D., Hermine O., Tough D.F., and Kaveri S.V. Modulation of dendritic cell maturation and function by B lymphocytes. J Immunol 175 (2005) 15-20
34. Tha-In T., Metselaar H.J., Tilanus H.W., et al. Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cells. Blood 110 (2007) 3253-3262
35. Siragam V., Crow A.R., Brinc D., Song S., Freedman J., and Lazarus A.H. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 12 (2006) 688-692
36. Bayry J., Lacroix-Desmazes S., Kazatchkine M.D., et al. Common variable immunodeficiency is associated with defective functions of dendritic cells. Blood 104 (2004) 2441-2443
37. Bayry J., Hermine O., Webster D.A., Levy Y., and Kaveri S.V. Common variable immunodeficiency: the immune system in chaos. Trends Mol Med 11 (2005) 370-376
38. Bayry J., Lacroix-Desmazes S., Donkova-Petrini V., et al. Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci U S A 101 (2004) 14210-14215
39. Bayry J., Lacroix-Desmazes S., Hermine O., Oksenhendler E., Kazatchkine M.D., and Kaveri S.V. Amelioration of differentiation of dendritic cells from CVID patients by intravenous immunoglobulin. Am J Med 118 (2005) 1439-1440
40. Bayry J., Kazatchkine M.D., and Kaveri S.V. Shortage of human intravenous immunoglobulin-reasons and possible solutions. Nat Clin Pract Neurol 3 (2007) 120-121